Patients receive navitoclax orally (PO) once daily (QD) on days 1-21 (days 1-28 course of 1 only) and sorafenib tosylate PO twice daily (BID) on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.